Becton, Dickinson and Company (BDX) fair value analysis

S&P 500 · Updated 2026-09-07

Becton, Dickinson and Company is a global medical technology manufacturer that produces and distributes a broad range of medical devices, laboratory equipment, and diagnostic products used in healthcare settings. The company operates in multiple regions including North America, Europe, Asia Pacific, and other international markets, serving hospitals, clinical laboratories, physicians' offices, and patients worldwide.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, BDX is trading at a 10–25% discount to estimated fair value.

BDX currently ranks #53 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 2 consecutive weekly runs.

Last price: $184.74
Sector: Healthcare
12-month range: $145.33–$201.91

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Moderate
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
52-week position: The upper-middle quarter of its range
DCF cross-check: Undervalued

What our data shows for BDX

Our model validated 17 trailing price-to-earnings windows for BDX, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $145.33–$201.91.
The 14-day relative strength index sits at a neutral 62.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for BDX
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent BDX news

TickrTrends' derived news-sentiment signal for BDX is currently mixed, computed from recent coverage.

Envetec Receives California Approval for GENERATIONS® to Treat Biohazardous and Sharps Waste (manilatimes.net, 2026-08-12)
TickrTrends take: Becton Dickinson's subsidiary Envetec obtained California regulatory approval for GENERATIONS technology to process biohazardous and sharps waste, expanding the company's addressable market in medical waste management. This approval represents progress in BD's diversification beyond traditional medical devices and diagnostics into waste treatment solutions, a segment that could support recurring revenue streams from healthcare facilities. For investors focused on valuation, the expansion of BD's waste management capabilities warrants monitoring as a potential growth driver that may not yet be fully reflected in the company's current undervalued assessment.

What people are saying

Follow the BDX conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for BDX showed notable shifts this week. The Relative Strength Index moved from the overbought zone into neutral territory, suggesting reduced upward momentum. Simultaneously, the valuation verdict improved from fairly valued to undervalued, indicating the stock may offer better value at current levels.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is BDX stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), BDX is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is BDX's TickrTrends verdict?

BDX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does BDX compare to other Healthcare stocks?

BDX ranks #53 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is BDX overbought or oversold?

BDX's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

BDX vs ENSG · BDX vs EW · BDX vs GMAB · BDX vs HCA · BDX vs KNSA